Treatment of Ulcerative Colitis With Rectal Instillation of Qinghua Quyu Prescription(QHQYP)
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study will enroll 60 patients with mild to moderate active ulcerative colitis as
subjects. They will be randomly divided into two groups: the TCM group received QHQYP rectal
instillation, while the control group received mesalazine enema. The treatment period for
both groups was 8 weeks. The modified Mayo Activity Index will be used as the main evaluation
index. Secondary evaluation indices will include the Underwater Endoscopic Severity Index
(UCEIS) score, endoscopic Baron score, mucosal histological score (Geboes index), Chinese
medicine syndrome efficacy evaluation, quality of life score, physicochemical indicators
reflecting disease activity or remission, intestinal microbiota indicators, and changes in
inflammation and immune-related indicators in colonoscopy biopsy tissues. Safety indicators
were also monitored.